|
| 37856781 | SLCO1B3 and SLCO2B1 genotypes, androgen deprivation therapy, and prostate cancer outcomes: a prospective cohort study and meta-analysis. | Carcinogenesis | 2024 |
| 37292833 | Evaluating Approaches for Constructing Polygenic Risk Scores for Prostate Cancer in Men of African and European Ancestry. | medRxiv | 2023 |
| 35637041 | A Healthy Lifestyle in Men at Increased Genetic Risk for Prostate Cancer. | Eur Urol | 2023 |
| 35932882 | A systematic review and in silico study of potential genetic markers implicated in cases of overactive bladder. | Am J Obstet Gynecol | 2023 |
| 36125519 | Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions. | Mol Cancer Res | 2023 |
| 35726641 | Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis. | Int J Epidemiol | 2023 |
| 37945903 | Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants. | Nat Genet | 2023 |
| 37898724 | Modifiable risk factors for subsequent lethal prostate cancer among men with an initially negative prostate biopsy. | Br J Cancer | 2023 |
| 37555839 | Germline Genetic Variants Associated with Somatic TMPRSS2:ERG Fusion Status in Prostate Cancer: A Genome-Wide Association Study. | Cancer Epidemiol Biomarkers Prev | 2023 |
| 36511902 | The Prostate Stromal Transcriptome in Aggressive and Lethal Prostate Cancer. | Mol Cancer Res | 2023 |
| 37139568 | Influence of Neighborhood Social and Natural Environment on Prostate Tumor Histology in a Cohort of Male Health Professionals. | Am J Epidemiol | 2023 |
| 37384841 | Free PSA and Clinically Significant and Fatal Prostate Cancer in the PLCO Screening Trial. | | 2023 |
| 37311464 | Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry. | Am J Hum Genet | 2023 |
| 36861107 | Addition of a Genetic Risk Score for Identification of Men with a Low Prostate-specific Antigen Level in Midlife at Risk of Developing Lethal Prostate Cancer. | Eur Urol Open Sci | 2023 |
| 35075214 | Metabolic syndrome and its pharmacologic treatment are associated with the time to castration-resistant prostate cancer. | Prostate Cancer Prostatic Dis | 2022 |
| 36103261 | Family History of Prostate and Breast Cancer Integrated with a Polygenic Risk Score Identifies Men at Highest Risk of Dying from Prostate Cancer before Age 75 Years. | Clin Cancer Res | 2022 |
| 35579976 | Circulating free testosterone and risk of aggressive prostate cancer: Prospective and Mendelian randomisation analyses in international consortia. | Int J Cancer | 2022 |
| 36125434 | Differences in Prostate Cancer Transcriptomes by Age at Diagnosis: Are Primary Tumors from Older Men Inherently Different? | Cancer Prev Res (Phila) | 2022 |
| 33792693 | Evaluation of a Multiethnic Polygenic Risk Score Model for Prostate Cancer. | J Natl Cancer Inst | 2022 |
| 35152271 | Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. | Prostate Cancer Prostatic Dis | 2022 |
| 35105480 | Finding a Place for Family History To Inform High-grade Prostate Cancer Risk. | Eur Urol | 2022 |
| 34939926 | Extent, impact, and mitigation of batch effects in tumor biomarker studies using tissue microarrays. | Elife | 2021 |
| 33956343 | A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer. | Prostate | 2021 |
| 33627383 | Association of Prediagnostic Blood Metabolomics with Prostate Cancer Defined by ERG or PTEN Molecular Subtypes. | Cancer Epidemiol Biomarkers Prev | 2021 |
| 33473200 | Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. | Nat Genet | 2021 |
| 33623038 | Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. | Nat Commun | 2021 |
| 33203692 | Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance). | Cancer Epidemiol Biomarkers Prev | 2021 |
| 33168599 | Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum. | Mol Cancer Res | 2021 |
| 33010161 | Recommended Definitions of Aggressive Prostate Cancer for Etiologic Epidemiologic Research. | J Natl Cancer Inst | 2021 |
| 33420416 | Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. | Prostate Cancer Prostatic Dis | 2021 |
| 33398198 | Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. | Nat Genet | 2021 |
| 35047751 | Circulating Insulin-Like Growth Factor 1-Related Biomarkers and Risk of Lethal Prostate Cancer. | JNCI Cancer Spectr | 2021 |
| 35079693 | DNA Repair Pathways and Their Association With Lethal Prostate Cancer in African American and European American Men. | JNCI Cancer Spectr | 2021 |
| 33158149 | The <i>CHEK2</i> Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. | Cancers (Basel) | 2020 |
| 31729902 | Genome-Wide Association Study for Urinary and Fecal Incontinence in Women. | J Urol | 2020 |
| 31811950 | Genetic Variant Associated With Survival of Patients With Stage II-III Colon Cancer. | Clin Gastroenterol Hepatol | 2020 |
| 32525914 | Clinical stage provides useful prognostic information even after pathological stage is known for prostate cancer in the PSA era. | PLoS One | 2020 |
| 32913135 | Multiplex Immunofluorescence in Formalin-Fixed Paraffin-Embedded Tumor Tissue to Identify Single-Cell-Level PI3K Pathway Activation. | Clin Cancer Res | 2020 |
| 32624279 | Inferior Cancer Survival for Men with Localized High-grade Prostate Cancer but Low Prostate-specific Antigen. | Eur Urol | 2020 |
| 31548585 | Publisher Correction: Shared heritability and functional enrichment across six solid cancers. | Nat Commun | 2019 |
| 30333152 | Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate. | Mol Cancer Res | 2019 |
| 30322655 | Re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. Eur Urol 2018;73:961-7. | Eur Urol | 2019 |
| 30622367 | Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. | Nat Genet | 2019 |
| 31222336 | Corrigendum: Loss of LDAH associated with prostate cancer and hearing loss. | Hum Mol Genet | 2019 |
| 30683880 | Shared heritability and functional enrichment across six solid cancers. | Nat Commun | 2019 |
| 31101764 | Identification of Novel Susceptibility Loci and Genes for Prostate Cancer Risk: A Transcriptome-Wide Association Study in Over 140,000 European Descendants. | Cancer Res | 2019 |
| 29167279 | Height, Obesity, and the Risk of <i>TMPRSS2:ERG</i>-Defined Prostate Cancer. | Cancer Epidemiol Biomarkers Prev | 2018 |
| 29892050 | Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. | Nat Commun | 2018 |
| 29892016 | Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. | Nat Genet | 2018 |
| 30169630 | Loss of LDAH associated with prostate cancer and hearing loss. | Hum Mol Genet | 2018 |